Cardarine Magnus

Catalogue entry: Cardarine Magnus. Labelled content: 10 mg/tablet. Listed pack: 60 tablets. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

Cardarine is the name commonly used for GW501516, a small-molecule PPAR-delta agonist. It does not act as an androgen-receptor modulator. Its placement within a SARMs-and-related-compounds catalogue is a browsing convention, not a pharmacological classification or evidence that the compounds share risks.

What the research measured

Narkar and colleagues studied AMPK and PPAR-delta pathways in Cell in 2008, using animal experiments to examine exercise-related metabolic adaptations. These findings help explain why Cardarine appears in endurance discussions. A mouse endurance endpoint is not a controlled human performance result and cannot identify a suitable consumer product.

Sporting claims and limitations

The compound's history includes serious safety concerns. A 2013 WADA alert reported that development had been terminated because of serious preclinical toxicities. This is a safety warning, not merely an anti-doping label. SR-9009 investigates a different target system; grouping the two as endurance compounds does not establish equivalent benefit, absorption or safety.

Product identity and documentation

When reviewing this item, separate the name GW501516, the selected labelled content and the actual composition of the supplied material. Appropriate documentation needs a lot-specific identity test and transparent analytical methods. A purity statement cannot resolve the development risks or establish a safe human exposure. Neither a favourable metabolic mechanism nor absence of androgen-receptor activity should be interpreted as reassurance.